1. Alexander J. Lepak and David R. Andes. Cepahalosporins. In Bennett J, Dolin R, Blaser MJ. (Eds) Principles and Practice of Infectious Diseases. 9th Ed, Philadelphia: Elsevier; 2020, pp:268-
284.
2. Bush K, Brasford PA. β-Lactams and β-Lactamase Inhibitors: An Overview. Cold Spring Harb Perspect Med. 2016 Aug 1;6(8): a025247.
3. Lin X, Kück U. Cephalosporins as key lead generation beta-lactam antibiotics. Appl Microbiol Biotechnol. 2022; 106(24): 8007–8020
4. Kurt H. Sefalosporinler. Güncel Gastroenteroloji Dergisi. Temmuz 1997. 197-202
5. Murray PR, Rosenthal KS, Pfaller MA. Antibacterial Agents. In: Medical Microbiology. 8th Ed, Philadelphia: Elsevier; 2016, pp:162-169.
6. Southwick FS. Anti-Infective Therapy. In: Southwick FS (Ed). Infectious Diseases:A Clinical Short Course, 4th Ed: China: McGraw Hill Medical Books, 2020, pp:1-63.
7. Arumugham VB, Gujarathi R, Cascella M. Third-Generation Cephalosporins. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.
8. Lima LM, Silva BNMD, Barbosa G, Barreiro EJ. β-lactam Antibiotics: An Overview From a Medicinal Chemistry Perspective. Eur J Med Chem. 2020 Dec 15; 208: 112829
9. Brooks GF, Carroll KC, Butel JS, Morse SA, Mietzner TA. Antimikrobik Kemoterapi. Tıbbi Mikrobiyoloji. Yenen OŞ. 1. Baskı, İstanbul: Nobel Tıp Kitabevleri, 2015, pp:371-405.
10. Cilloniz C, Pericàs JM, Rojas J. Ceftaroline in severe community-acquired pneumonia. Rev Esp Quimioter. 2022; 35(Suppl 1): 28–30.
11. Holland TL, Cosgrove SE, Doernberg SB et al. Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia. N Engl J Med. 2023 Oct 12;389(15):1390-1401.
12. Sanz Herrero F. Ceftazidime-avibactam. Rev Esp Quimioter. 2022; 35(Suppl 1): 40–42.
13. Matesanz M, Mensa J. Ceftazidime-avibactam. Rev Esp Quimioter. 2021 Sep; 34(Suppl1):38-40.
14. Shirley M. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram–Negative Bacterial Infections. Drugs. 2018 Apr;78(6):675-692
15. López Montesinos I, Montero M, Sorlí L, Horcajada JP. Ceftolozane-tazobactam: When, how and why using it? Rev Esp Quimioter. 2021; 34(Suppl1): 35–37.
16. Van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β Lactam/β-Lactamase Inhibitor Combinations. Clin Infect Dis. 2016 Jul 15; 63(2):
234–241.
17. Kars B, Öztaş S, Altındiş M. Bir İlaç Monografı; Sefiderokol. J Biotechnol and Strategic Health Res. Nisan 2023;7(1):9-25.
18. McCreary EK, Heil EL, Tamma PD. New Perspectives on Antimicrobial Agents: Cefiderocol. Antimicrob Agents Chemother. 2021 Aug; 65(8): e02171-20.
19. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma
and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010 Oct;105(4):259-273.
20. Antimicrobial agents. In “Infectious Diseases Subspecialty Consult” eds. Kirmani N, Woeltje K, Babcock H, Washington Manual Series, Volters Kluwer/Lippincott, Williams &Wilkins, 2nd
ed, 2013, pp:429-472.
21. Dağlar D, Öngüt G. Genişlemiş Spektrumlu Beta-Laktamazlar (GSBL) ve Tanı Yöntemleri. İnönü Üniversitesi Sağlık Bilimleri Dergisi 2012; 1: 1-9.
22. Tooke CL, Hinchliffe P, Bragginton EC, Colenso CK, Hirvonen VHA, Takebayashi Y, Spencer J. β-Lactamases and β-Lactamase Inhibitors in the 21st Century. J Mol Biol. 2019 Aug 23; 431(18):
3472-3500.
23. Uyar NY, Ayaş MK, Aksaray S. Prevalence of Extended-Spectrum Beta-Lactamase Producing Klebsiella: Cross-Sectional Study, 2000- 2021. East J Med. 2023 28(1): 165-171
24. Yılmaz N, Ağuş N, Bayram A, Şamlıoğlu P, Şirin MC, Derici YK, Hancı SY Antimicrobial susceptibilities of Escherichia coli isolates as agents of community-acquired urinary tract infection
(2008–2014).Turk J Urol. 2016 Mar;42(1):32-6.